Weekly belimumab is associated with greater benefit than placebo for patients with hypocomplementemic/anti-double stranded (ds)DNA-positive systemic lupus erythematosus.
In the absence of an effective pharmacotherapy for systemic sclerosis, researchers suggest stem cell transplant may have potential in the management of cutaneous and internal organ manifestations.
The consideration of additional variables, such as skin biopsy, should be used to involve more patients and prevent the inclusion of any cutaneous diseases that mimic ADM.
Dermatology Advisor Articles
- Botulinum Toxin Type A Effective for Treating Rosacea Facial Flushing
- Acne Lesions, Scars Treated With Cooling Vacuum-Assisted Erbium:Glass Laser
- Psoriasis Linked With Higher Risk for Sexual Dysfunction
- New Psoriatic Arthritis Guidelines Recommend TNFi as First-Line Tx Option
- AMA Survey Collects Advice for Physicians Approaching Retirement
- Common Skin Conditions in People of Color: Identification and Treatment
- Subcutaneous Dupilumab Initiates Hair Regrowth in Patient With Alopecia Totalis, Atopic Dermatitis
- Rosacea Improves With Anti-Inflammatory Effect of Brimonidine Gel
- Can Examining Marginalization Identify Gaps in Medical or Nutritional Care?
- Mohs Surgery Alone Associated With Improved Outcomes in High-Risk Squamous Cell Carcinoma
- Secukinumab Superior to Placebo for Treatment of Moderate to Severe Nail Psoriasis
- Diagnostic Challenges of Neutrophilic Dermatosis May Lead to Misdiagnosis
- EMS Times Longer for Patients From Poorest Neighborhoods
- Most Insured Patients Not Using Online Portals
- Overcoming the Barriers to Including Pregnant Women in Clinical Trials